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Abstract
Background: Tobacco control is an area where the translation of evidence into policy would seem to be 
straightforward, given the wealth of epidemiological, behavioural and other types of research available. Yet, even here 
challenges exist. These include information overload, concealment of key (industry-funded) evidence, 
contextualization, assessment of population impact, and the changing nature of the threat.
Methods: In the context of Israel's health targeting initiative, Healthy Israel 2020, we describe the steps taken to 
develop a comprehensive tobacco control strategy. We elaborate on the following: a) scientific issues influencing the 
choice of tobacco control strategies; b) organization of existing evidence of effectiveness of interventions into a 
manageable form, and c) consideration of relevant philosophical and political issues. We propose a framework for 
developing a plan and illustrate this process with a case study in Israel.
Results: Broad consensus exists regarding the effectiveness of most interventions, but current recommendations differ 
in the emphasis they place on different strategies. Scientific challenges include integration of complex and sometimes 
conflicting information from authoritative sources, and lack of estimates of population impact of interventions. 
Philosophical and political challenges include the use of evidence-based versus innovative policymaking, the 
importance of individual versus governmental responsibility, and whether and how interventions should be prioritized.
The proposed framework includes: 1) compilation of a list of potential interventions 2) modification of that list based 
on local needs and political constraints; 3) streamlining the list by categorizing interventions into broad groupings of 
related interventions; together these groupings form the basis of a comprehensive plan; and 4) refinement of the plan 
by comparing it to existing comprehensive plans.
Conclusions: Development of a comprehensive tobacco control plan is a complex endeavour, involving crucial 
decisions regarding intervention components. "Off the shelf" plans, which need to be adapted to local settings, are 
available from a variety of sources, and a multitude of individual recommendations are available. The proposed 
framework for adapting existing approaches to the local social and political climate may assist others planning for 
smoke-free societies. Additionally, this experience has implications for development of evidence-based health plans 
addressing other risk factors.
Background
Controlling tobacco use, the leading preventable cause of
death in the world today [1], remains an elusive goal. The
combination of the addictive nature of smoking, industry
activity, and tax revenue to governments complicate con-
trol attempts. Greater understanding of the enormity of
the tobacco-related disease burden has highlighted the
importance of controlling active and involuntary expo-
sure.
Because individual measures have limited effectiveness,
and groups of strategies implemented together seem to
offer greater promise than individual strategies [2], com-
prehensive plans for tobacco control have gained popu-
larity. The policy maker has no shortage of sources of
advice. The US Centers for Disease Control [2,3], the
WHO's Framework Convention for Tobacco Control [1]
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(FCTC) [1] and MPOWER [4], the US National Institutes
of Health [5], and the US Institute of Medicine [6], and
have been joined by individual US states [7-9], countries
worldwide [10] and leading tobacco control activists
[11,12] in proposing comprehensive plans. Meanwhile,
evidence for the effectiveness of individual measures has
been reviewed by various organizations, for example, the
Cochrane Collaboration, the US Task Force for Commu-
nity Preventive Services [13] the US Preventive Services
Task Force [14], the US Public Health Service [15], and
Britain's National Institute for Health and Clinical Excel-
lence (NICE) [16].
Faced with these myriad sources of information, the
salient question facing policy makers is: Which strategies
and interventions should be included in the plan? To
answer this, policy makers must address both scientific
and philosophical issues in the context of the local politi-
cal constraints. Recommendations with a strong evidence
base may not be politically feasible. For example, subsi-
dizing cessation services has been proven to increase ces-
sation, yet, a society with a strong emphasis on individual
responsibility may oppose such a move. Likewise,
increasing the excise tax on cigarettes and earmarking
percentages of the increased revenue for tobacco control
activities will inevitably provide an important resource
for tobacco control, but some finance ministries oppose
earmarking of funds as it restricts their freedom to set
budgets. Proposed measures must also be adapted to the
ability of states to enforce measures.
Extensive scientific evidence and related recommenda-
tions for practice are available. These include interven-
tions at both the individual level, as well as those geared
for entire communities, for large organizations, and com-
prehensive programs at the national and international
levels. Philosophical and political issues such as the
degree of reliance on pure scientific evidence, the desir-
ability of, and best method to prioritization interventions,
and the best strategy to designate ultimate responsibility
for tobacco control, have been less well addressed.
Methods
In this paper we propose a framework for developing
comprehensive tobacco control plans. We address scien-
tific issues affecting choice of strategies and interven-
tions; suggest a system to organize the existing evidence
into a manageable form; discuss the philosophical and
political issues that arise in the course of such an endeav-
our; and present a systematic means of adapting scientific
knowledge, philosophic principles, and policy recom-
mendations to the local setting. As a case study, we report
the Israeli experience in developing a national plan rele-
vant to local needs, aspirations, and means.
Process of development of an Israeli comprehensive 
tobacco control plan
The Healthy Israel 2020 initiative was created in 2005
with a mandate to develop national health targets and
recommend evidence-based interventions necessary to
achieve them [17]. The Health Behaviors committee is
one of its 21 committees. The Tobacco Control Subcom-
mittee (subsequently referred to as "the Committee) is a
leading subcommittee thereof. It is comprised of 24
national leaders in tobacco control, from the government,
non-governmental organizations, health maintenance
organizations, and academia, and is strengthened by sup-
port from international consultants. A consensus-based
process was used for decision making.
From 2005-2008, the Committee met regularly to
develop health objectives, set quantitative targets for each
objective, and develop a set of strategies and specific
interventions to achieve them. Concomitantly, members
collaborated to produce a summary of the existing evi-
dence to serve as the backbone for writing recommenda-
tions for interventions.
Initially, the leadership of Healthy Israel 2020 envi-
sioned the following multi-stage process for selecting a
set of interventions necessary to reach the health targets:
1 - Evidence-based interventions were to be selected
from various sources, including the Cochrane Collabora-
tion, the US Preventive Services Task Force, the US Task
Force on Community Preventive Services, and other liter-
ature reviews and original studies, ranked by level of evi-
dence.
2 - Interventions were to be selected from the resultant
list based on current patterns of tobacco use in Israel, fea-
sibility of implementation, and the existing political con-
straints.
3 - The items were to be prioritized on the basis of their
potential future impact, quality of the evidence of effec-
tiveness, and their generalizability as gleaned from the
scientific literature. The information from the scientific
literature was to be complimented by local evidence and
the Committee's expert opinion on feasibility of imple-
mentation. Cost, cost-effectiveness, and issues of inequal-
ity were also to be considered.
The final product was to be a prioritized list of inter-
ventions.
Results and Discussion
Scientific issues affecting choice of strategies
Challenges in developing evidence-based tobacco control
policy are summarized below.
Information overload
Information overload is a problem common to guideline
development in many areas of medicine and public health
[18]. Thousands of studies and hundreds of reviews have
been published on the effectiveness of individual inter-Rosen et al. Health Research Policy and Systems 2010, 8:17
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ventions for tobacco control, as have numerous compre-
hensive plans. Reviewing all of the evidence is rarely a
feasible strategy for those developing plans. Yet, even a
review of reviews in this field is challenging, especially as
reviews may be of varying quality and produce conflicting
results [19]. An alternative is to draw on authoritative
sources of systematic reviews, and base recommenda-
tions on interventions proposed by leading agencies.
However, these are written from various perspectives
and, when prepared by national bodies, reflect their par-
ticular circumstances.
Accessibility of important evidence
Conventionally, public health professionals seek evidence
from the published literature. However, in the case of
tobacco, much research was done by the industry with
the explicit intention that it not be published. Further-
more, some research that has been published was under-
taken with the explicit aim of confusing the picture, as
part of a process of denialism, used not only by the
tobacco industry but also others in, for example, the oil
and alcohol industry [20]. A wealth of material is now
available from the industry's internal documents, now in
the public domain following litigation in the USA: it is
here that much evidence on the toxicity of second-hand
smoke is to be found [21,22]. These documents are also
an important source of evidence on effectiveness of poli-
cies, on industry perceptions of their effectiveness, and
may provide country-specific information on industry
tactics. Although an increasing amount of this material is
now being published by researchers analysing these doc-
uments, there is still a great deal that has yet to be stud-
ied, and especially material that relates to the activities of
the tobacco industry in individual countries.
Uneven quality of the evidence base
The strength of scientific evidence for interventions var-
ies [23], and policy makers must decide when there is suf-
ficient evidence to act. Many governments acted long
before there was conclusive biological evidence that
smoking caused cancer or heart disease. In retrospect,
these actions did, indeed, prove prescient [24].
The situation is more complicated when deciding about
specific interventions. Measures that, intuitively, seem
worthwhile may turn out to be ineffective or even harm-
ful: for example, the youth anti-smoking campaigns spon-
sored by the tobacco industry portrayed smoking as adult
behaviour, but in doing so may have actually increased
the probability of initiation [25].
The classical hierarchy of evidence [26] forming the
basis of many medical decisions is primarily premised
upon internal validity. Other forms of research with
greater potential impact may be assigned low scores. In
tobacco control, much of the effort takes place in the pol-
icy arena, where controlled trials may be difficult or
impossible to implement. Thus, unrelated to actual effec-
tiveness, the clinical interventions which are assessed
with randomized controlled trials have an inherent
advantage. A further problem is that external validity is
often not addressed [27], so policy makers may have diffi-
culty determining whether interventions will work in dif-
ferent populations and settings.
Population impact often unavailable
Most research papers and many systematic reviews pro-
vide estimates of effectiveness of interventions. However,
in the policy setting, a point estimate of effectiveness pro-
vides insufficient information on which to base policy.
The important outcome is population impact: How much
will implementing this particular strategy affect tobacco
use in the population as a whole?
As an example of the difference between these parame-
ters, consider brief physician-based counselling for cessa-
tion. This has been shown to increase quit rates by 74%,
corresponding to an absolute increase of 1%-3% in quit
rates [28]. Yet, the population impact of such counselling
remains unknown. Although it is possible to develop pre-
dictive models, the data needed to populate them are
often lacking. Calculation would require knowledge of
the percentage of physicians who counsel or would be
willing to counsel [29] and frequency of physician visits
by smokers at different ages (as the expected change in
life expectancy secondary to cessation is a function of the
age of quitting).
The need for innovation: keeping up with the tobacco 
industry
Notwithstanding the limitations of the available evidence,
there is a clear imperative that public health policy should
draw on what does exist to the extent possible. Since the
tobacco industry is constantly seeking to stay one step
ahead of the tobacco control community, there is a con-
tinuing need for innovation. One contemporary example
is the need to address the marketing of smokeless tobacco
[30,31], increasingly recognised as a tactic to maintain
levels of addiction among individuals who might other-
wise be weaned off nicotine in smoke-free settings [32],
as well as to entice new users. For example, it has now
been shown that those who use both cigarettes and oral
tobacco have higher rates of nicotine addiction than those
using either alone. Thus, it is important to be aware of the
growing evidence of effectiveness of measures to limit the
use of smokeless tobacco and of the increasing involve-
ment of the traditional cigarette companies in the smoke-
less tobacco market, a situation that enables them to
circumvent actual and potential marketing restrictions.
Another is action against product placement in films
[33]. Although the tobacco industry has been paying
actors and studios to promote its products since the
1930s, the scale on which it operated has only recently
become apparent [34]. However, the prevalence of smok-
ing in movies declined until the early 1980s, coincidingRosen et al. Health Research Policy and Systems 2010, 8:17
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with falling rates in the general population. Since then it
has  incr eased,  so t ha t  a ct ors  in mo vies  a r e  now  m uc h
more likely to smoke than those they are portraying [35].
These findings have stimulated tobacco control research-
ers to ask why, revealing that cumulative exposure to
smoking in movies significantly increases the probability
that a young adult will smoke [36], with a subsequent ran-
domised controlled trial finding that among young smok-
ers exposed to smoking or non-smoking images, the
former were more likely to smoke in the break after view-
ing the images than the latter [37]. This has led some
public authorities (e.g., in England and California) to con-
sider requiring films containing smoking scenes to have
an adult rating [38]. However, even though such mea-
sures have yet to be implemented, they may already need
to be adapted given evidence of the use of televised trail-
ers to portray smoking scenes to those who may not be
able to view the actual movies legally [39]. A third is the
way in which the industry is circumventing measures of
packaging. For example, the New Zealand government's
attempts to get manufacturers to remove misleading
descriptors such as "light" was undermined by the explicit
association of what was portrayed as lightness or mild-
ness with certain colours that remained in use after the
words had been removed and by the use of synonyms
such as "subtle" or "mellow"[40]. These and other findings
on how people perceive packaging [41] provide a strong
case for requiring cigarettes to be sold only in plain pack-
ages.
These examples are important because none of them
are addressed in existing recommendations. Thus, those
involved in tobacco control must constantly keep up to
date with the tactics adopted by the tobacco industry to
circumvent controls and the evidence for new approaches
to control. This involves familiarity with the medical and
social research literature, the industry's trade media, and
research using the industry's internal documents.
Review of the scientific evidence
Specific interventions
The evidence related to specific interventions is summa-
rized in Additional File 1, Table S1, and draws on system-
atic reviews from the Cochrane Collaboration (4th quarter
2008) [42], the US Preventive Services Task Force [14],
and the Task Force on Community Preventive Services
[13]. A similar review of the evidence was published in
2001, nearly a decade ago[43]. Interventions reviewed
took place in clinical and community settings, and
spanned legislation, enforcement, taxation, medical
financing, communication, education, and clinical pre-
vention. The three main activities were prevention of
uptake (especially among youths and young adults), ces-
sation, and prevention of exposure to second hand
smoke. Effectiveness of cessation medications was
recently reviewed elsewhere [15] and is not addressed
here.
Tax increases, legislation and enforcement of smoking
bans and restrictions, mass media campaigns, workplace
interventions, and quitlines are effective strategies in
community settings. In the clinical setting, screening and
brief advice by health professionals, pharmacotherapy,
and counselling (individual and group) are effective. Sub-
sidizing the cost of cessation and provider reminder sys-
tems is effective at the health system level. School-based
approaches have limited effectiveness.
Comprehensive plans
Comprehensive strategies have been proposed by author-
itative bodies including the WHO (the FCTC [1], and the
MPOWER program [4]), the IOM (Blueprint for the
Nation on Ending the Tobacco Problem [6]), and the US
CDC (Best Practices for Comprehensive Tobacco Control
Programs [3]).
The plans differ in how they address the tension
between evidence-based and innovative policymaking.
CDC Best Practices and MPOWER were primarily based
on evidence-based interventions. The FCTC is a negoti-
ated document based on consensus of members of partic-
ipating states, rather than a direct report of scientific
evidence. The IOM report is two-pronged: the first prong
is based on evidence, while the second is comprised of
innovative techniques.
The "building blocks" of these proposed programs are
summarized in Table 1. Most recommend surveillance
and research, with a consensus on the need to monitor
the prevalence of tobacco use. MPOWER, the FCTC, and
the CDC all recommend monitoring of tobacco policy.
Protecting the public from second hand smoke exposure
is recommended by all, though the specific measures
vary. Only the IOM explicitly recommends bans in cars
carrying children, smoke-free apartment buildings, and
advice by healthcare providers on the dangers of second-
hand smoke.
All of the organizations recommend helping smokers
quit, using a similar set of strategies: medical advice,
pharmacotherapy, quitlines, counselling, and subsidizing
costs of the aforementioned interventions.
All of the organizations advocate warning the public
about dangers via health communication. Enforcement or
implementation of tobacco advertising bans, or bans on
tobacco promotion and sponsorship, are mentioned in all
of the plans, though the CDC leaves the details to individ-
ual states.
Tobacco tax increases are recommended by all organi-
zations. The FCTC uniquely addresses tobacco supply as
well as demand, and also has provisions for assisting
farmers and producers of tobacco products to find alter-
native employment.Rosen et al. Health Research Policy and Systems 2010, 8:17
http://www.health-policy-systems.com/content/8/1/17
Page 5 of 13
Table 1: Comparison of strategies from international comprehensive tobacco control plans
MPOWER CDC Best Practices Institute of Medicine Framework Convention 
for Tobacco Control
MONITORING AND RESEARCH √√ √
Monitor prevalence of tobacco use √ √ Article 20
Monitor attitudes, knowledge, or social norms √ Article 20
Monitor tobacco industry marketing, promotion 
and lobbying
√A r t i c l e  2 0
Monitor tobacco production and manufacture Article 20
Monitor policies, impact of policies √ √ Article 20
Assess effectiveness and impact of programs √ √ Article 20
Research on consequences of tobacco use and 
exposure
√A r t i c l e  2 0
Research on determinants of tobacco use and 
exposure
√√ A r t i c l e  2 0
Identification of alternative crops Article 20
PROTECT PEOPLE FROM SECONDHAND 
SMOKE
√ √ (Details left to States) √ √
Prohibition of smoking in all indoor non-
residential environments
√√ A r t i c l e  8
Full enforcement √
Voluntary home smoking bans in homes with 
children
√√
Healthcare provider messages on SHS √
Car bans with children passengers √
Smoke-free apartment buildings √
OFFER HELP TO QUIT (AND ENCOURAGE 
QUITTING)
√√ √ √
Medical advice √ √ √ Article 14
Pharmacotherapy √ √ √ Article 14
Quit lines √ √ √
Counselling √ √ √ Article 14
Provider training/providing trained personnel √ √ √ Article 12
Subsidize costs √ √ √ Article 14
WARN ABOUT DANGERS √√ √ √
Warn about dangers √ √ √ Article 12
Advertising campaigns about active smoking √ √ √
Advertising campaigns about involuntary 
smoking
√√
Warnings on packs √ √ Article 11.
FDA authority to regulate warnings √
YOUTH PREVENTION √√ √ √
Funded school programs √ √
Media campaigns √ √ √
Limit youth access √ √ Article 16
COMMUNITY, STATE, FEDERAL, AND 
INTERNATIONAL ACTION
√√ √ √
Establishment of a coordinating body for tobacco 
control
Article 5Rosen et al. Health Research Policy and Systems 2010, 8:17
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Far-reaching regulatory activity at the federal level is
recommended by the IOM, much of it identical to the
FCTC recommendations. The IOM also recommends
mandatory reduction in the nicotine content of tobacco
products.
Planning and administration at the state and commu-
nity level are stressed by the CDC, along with the cre-
ation of a strategic plan. The FCTC recommends creation
of a body with responsibility for tobacco control.
The CDC emphasizes tobacco-related disparities and
supports addressing them through culturally appropriate
interventions.
Philosophical and political issues integral to the planning 
process
Little has been written to date regarding philosophic
issues confronted by policy makers in developing com-
prehensive tobacco control plans. The main issues are
summarized below.
Overarching goals: A function of societal values
The first step in the planning process is to agree on the
overarching goals. While this may seem obvious at the
outset, it is actually complex as it must take into account
societal values and political preferences, and should be
consistent with broader health policies. Thus, a policy
designed to reduce the overall tobacco-attributable dis-
ease burden may conflict with one seeking to reduce
health disparities: some interventions may be most effec-
tive among groups who are relatively privileged, so that
average health improves but disparities widen. A goal of
reducing current prevalence of tobacco use will lead to
somewhat different priorities than one of reducing future
preventable tobacco-related disease. Policies should be
aligned with stated goals.
Individual or governmental responsibility?
Decisions made by policy makers implicitly reflect philo-
sophical beliefs about the balance of governmental and
individual responsibility for health. This is a subject rife
with inconsistencies [44].
A decision to develop a comprehensive plan presup-
poses a role for government in tackling the harm caused
by tobacco, a principle enshrined in the FCTC and one
which most states have ratified. However, it cannot be
assumed that this view is held de facto by decision-mak-
ers. Their preferences are rarely explicit, but may be
inferred from the nature of existing policies.
Many WHO members still have much to do to imple-
ment the provisions of the FCTC. Obstacles include ideo-
logical opposition to state action in areas that can be
p o r t r a y e d ,  e v e n  i f  i n c o r r e c t l y ,  a s  p e r s o n a l  c h o i c e ,  t h e
strength of corporate interests, and a failure to balance
tax revenues from cigarettes against the cost of smoking-
Comprehensive state tobacco control programs √ √
Link with chronic disease programs √
Identify tobacco-related disparities between 
population groups
√√
Create tobacco-free social norms √
Funding strategy √ √ √ Article 26
Training and support for researchers Article 20
Cooperate with WHO on research, report and 
exchange of information; Cooperation in 
scientific, technical, and legal fields
Article 20, 22
REGULATION AND LITIGATION √√ √ √
Raise taxes/Prices √ √ √ Article 6
Enforced bans, bans, or restrictions on tobacco 
advertising, promotion, sponsorship
√√ √ A r t i c l e  1 3
Regulation of manufacture, distribution, 
marketing, and use by FDA or other regulatory 
agency
√ Articles 9, 15
Tobacco product disclosure √ Article 10
Disclosure of research by industry √
Reduce nicotine level √
Support for economically viable alternative 
activities
Article 17
Litigation/Liability Article 19
Table 1: Comparison of strategies from international comprehensive tobacco control plans (Continued)Rosen et al. Health Research Policy and Systems 2010, 8:17
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related disease. Even in countries which are loathe to reg-
ulate industry or individual behaviour, there is often con-
sensus on the need to protect citizens from second-hand
smoke. Thus, many American cities and states have
passed smoke-free air laws. The State of New York goes
beyond this, currently providing free nicotine replace-
ment therapy to smokers.
For these reasons it will often be necessary to explicitly
address beliefs about the relationship between individu-
als, corporations, and governments that underlie any
plan, addressing the question of what elements of tobacco
control are legitimate areas for government action [45].
In principle, individuals should be allowed to make their
own decisions about how they lead their lives, as long as
those decisions meet certain criteria. First, all costs and
benefits should be private, affecting no-one else. This is
clearly not the case with tobacco, because of the direct
harm caused by second-hand smoke and the societal
costs resulting from the reduced productivity of smokers
who are unwell or die prematurely. Second, the decision
should be rational, maximising their utility by weighing
costs and benefits. The empirical lack of rationality in
decisions made by children and the problem of nicotine
addiction in adolescence [46] provides a justification for
action to limit smoking in this age group. Third, individu-
als should have accurate, up-to-date information, and not
be affected by "optimism bias" which would lead them to
believe that they are at less at risk than others [47]. Again,
there is substantial evidence that both the risk to health
and the addictive nature of tobacco are underestimated
[48]. Fourth, individuals should be time-consistent, bal-
ancing long-term harms against instant gratification. In
reality, the latter is given much greater weight than the
former. For all of these reasons, there is a powerful case
for government action, but the argument must be made
clearly.
Yet another reason for developing a consistent set of
principles is to prevent manipulation by the tobacco
industry. The industry and its front organizations will
focus attention on any inconsistencies, while invoking the
"slippery slope" argument to portray any attempt to con-
trol smoking as the first step towards either a "nanny
state" or a totalitarian regime controlling all aspects of life
[49]. Clarity about principles is also helpful in gaining
support for individual policies that, although effective,
may pose difficulties for some politicians. In this context,
there is a strong case for advertising that explicitly coun-
ters arguments made by the tobacco industry and sheds
light upon tactics used to subvert effective health policies
[50].
Prevention, cessation, or reduction of secondhand smoke 
exposure?
Prevention, cessation, and reduction of second-hand
smoke exposure are all essential elements of a compre-
hensive plan. Changes in any of these three elements
impacts the others: prevention of uptake and smoking
cessation lead to reduced second-hand smoke exposure;
interventions which reduce second-hand smoke exposure
also reduce prevalence of smoking (in part because they
denormalize the act of smoking and make life more diffi-
cult for smokers) [51], and prevention of smoking initia-
tion obviates the need for cessation interventions.
Deciding what to prioritize involves philosophical and
scientific considerations. Those who believe that the indi-
vidual bears sole or primary responsibility for smoking
will be less likely to advocate government expenditure on
cessation medications and other aids. Protection of non-
smokers in public places may be more acceptable to these
fierce individualists.
Advocates of prevention focus on the advantage of
intervening before addiction occurs. Advocates of cessa-
tion point out the quicker impact on disease burden that
cessation will bring, due to the long lag time for the devel-
opment of many smoking-related illnesses [52], as well as
the immediate benefits of cessation for smokers [53].
Cessation proponents also point to the limited effective-
ness of many prevention strategies. A further issue is age.
When prevention is the objective, youth tend to be tar-
geted; on the other hand, cessation efforts generally focus
on adults. Even among adults, a case can be made for dif-
ferential targeting, as younger adults have more to gain
than older adults [54]. Yet withholding cessation aids
from older adults is ageist.
Can evidence of effectiveness of interventions from other 
countries be generalized to a local setting?
A central question is whether information about effec-
tiveness of interventions is transferrable between coun-
tries. Social norms and political climates differ
substantially, so a strategy which is feasible or effective in
one country or region or society may be impossible to
implement or ineffective in another setting. Much of the
available evidence is produced in the developed nations,
which have the resources to both deliver the interven-
tions and assess their effectiveness.
Some of the evidence base is built on research per-
f o r m e d  i n  a  v a r i e t y  o f  c o u n t r i e s ,  s u c h  a s  t h a t  o n  t h e
effects of smoke-free air laws. Yet, even that literature is
mostly limited to research performed in Western nations,
and generalization to countries with deficient public
compliance to governmental regulation is problematic.
Hence, transferring evidence which can be found in the
literature from other countries, societies, or cultures may
not represent the effectiveness or feasibility of an inter-
vention in another place or time. On the other hand, evi-
dence is likely to be sparse from smaller or less developed
countries. Dismissing evidence, and in particular, robust,
multi-national evidence simply because it comes from
elsewhere, would not benefit countries without the
resources to perform their own research.Rosen et al. Health Research Policy and Systems 2010, 8:17
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Prioritized list versus comprehensive programme
Policy makers must decide whether to recommend a
comprehensive package or a prioritized list of interven-
tions. Some public health bodies, such as the Partnership
for Prevention, produce prioritized lists of preventive
interventions under the assumption that policy makers
seek such guidance to maximize the impact of their lim-
ited health budgets. Current recommendations from
organizations reviewed here recommend comprehensive
policies as opposed to prioritized lists, largely because of
mounting evidence that interventions work better in
combination than separately [3]. However, a recent
review of implementation of the CDC Best Practices [55]
is instructive: It showed that most state-run tobacco con-
trol programs do not receive the minimum levels of fund-
ing recommended by the CDC. States have been forced to
decide between implementing only some of the interven-
tions, or allocating partial funding for each element. So,
prioritization inevitably takes place, albeit at a later stage.
Policy makers should consider the possibility of explicit
prioritization at the outset. Alternatively, policy makers
might strategically prioritize to optimize their effective-
n e s s  b y  t i m e ,  t h a t  i s ,  b y  d e c i d i n g  w h i c h  i n t e r v e n t i o n s
would best be done first. For example, it may be worth-
while to first build popular support for legislation
through investing in mass media approaches, and only
afterwards endeavour to pass legislation.
Case Study: Development of a national tobacco control 
plan within the context of Healthy Israel 2020
Actual process
The actual process used by the Committee was substan-
tially modified during the course of deliberations. The
first change came about because some Committee mem-
bers were interested in submitting proposals for innova-
tive interventions, which did not have the advantage of
supporting evidence. On the one hand, this went against
the grain of a truly evidence-based plan; on the other,
innovation in tobacco control is crucial to counter the
continually-changing tactics of the tobacco industry. So it
was decided to allow innovative interventions. Like the
evidence-based interventions, these had to undergo
approval by the full Committee. Further, the innovative
nature of these interventions was duly noted, in the con-
text of the transparent rankings of the evidence base
which were provided for all interventions.
A further issue which arose was the fact that there was
little local evidence regarding effectiveness of interven-
tions. We found and used what little local evidence we
c o u l d .  F o r  t h e  m o s t  p a r t ,  h o w e v e r ,  w e  w e r e  f o r c e d  t o
choose between using the available evidence, even
though it came from outside of Israel, or having almost
no evidence to use. We chose the former, but considered
local cultural, social, and political norms when making
our plan.
The most significant change to the program occurred
when we reached what was to be the final stage of the
work: prioritization of the various interventions. Like all
the Healthy Israel 2020 Committees, we were tasked with
not simply providing a list of interventions, but with pro-
viding a prioritized list of interventions. The details of
how to prioritize were to be determined by the Commit-
tee and based on a combination of potential future
impact on disease burden, quality of the evidence of
effectiveness, generalizability, equity, cost, cost-effective-
ness, and feasibility.
As we began to consider different options for prioritiza-
tion, we were confronted with three serious problems:
i. We could not find a single measure on which to pri-
oritize which was acceptable to the committee. Bal-
ancing the needs of future population impact, equity,
strength of evidence, and cost did not lend itself to
any kind of straightforward prioritization; further,
estimates for most of these measures were not easily
available, and estimation was beyond the scope of the
2020 initiative.
ii. The list which we had developed included 76 inter-
ventions. This was unwieldy and also had many inter-
ventions which were similar.
iii. As we delved farther into the literature on tobacco
control policy and comprehensive tobacco control
plans, we found evidence that the most effective poli-
cies were not based on single strategies or prioritized
lists of interventions, but on multi-component plans
in which the different components complimented one
another.
We grappled with these three issues in a full Committee
meeting. In a breakthrough decision, we decided to move
away from the concept of a long, prioritized list of inter-
ventions and, instead, adopted the concept of a compre-
hensive plan based on a much smaller number of grouped
interventions. These broad categorizations would include
multiple individually-related items, but would be unpri-
oritized: the idea was that they would be recommended
as a set of strategies instead of as a prioritized list. We
considered categorizations based on various factors (for
example: setting (community, school, clinical) or targeted
outcome (prevention, cessation, second hand smoke));
before deciding on the groupings listed below.
Once we had created the main strategic groupings, we
sorted the individual interventions into the groups and
then compared our categories with existing comprehen-
sive plans. We made some revisions on the basis of these
existing plans before finalizing our plan.
The final framework for developing the plan is illus-
trated in Figure 1. The process had four distinct stages:Rosen et al. Health Research Policy and Systems 2010, 8:17
http://www.health-policy-systems.com/content/8/1/17
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1 - Compilation of a list of potential interventions based
on
• Comprehensive review of interventions reviewed by
the Cochrane Collaboration, and/or recommended by
the US Preventive Services Task Forces, and the US
Task Force for Community Preventive Services.
• Ad hoc review of interventions examined by other
reviewing agencies, particularly the UK's National
Institute for Clinical Excellence, The US Public
Health Service Clinical practice guideline: Treating
Tobacco Use and Dependence: 2008 Update, and the
scientific literature
• Innovative ideas suggested by Committee members.
2 - Modification of that list based on local needs and
the prevailing political climate
We qualitatively considered relevance to the Israeli
situation, practicability, the current political climate,
and potential population impact (to the extent possi-
ble). Exclusions were primarily based on lack of polit-
ical feasibility. Thus, for example, legislating
decreased nicotine content was not considered feasi-
ble, as most Israeli cigarettes are imported. While a
call for increased excise taxes was included, a call for
earmarking part of that income for tobacco control
activities was not, due to the known opposition of the
Treasury to earmarking of funds.
3 - On the basis of the list, creation of broad groupings
of interventional strategies to form the basis of a compre-
hensive plan
The broad categories were to cover all the main ele-
ments of tobacco control. In many cases, similar strat-
egies are important for different goals. For example,
mass media is important for prevention of smoking
initiation, cessation, and reduction of second hand
smoke exposure. Constructing the categories was
influenced by the existing evidence for effectiveness.
School interventions, for example, were not defined
as a separate category because of the dearth of evi-
dence for effectiveness from these interventions.
Interventions were categorized into eight broad strat-
egies (Taxation, legislation, enforcement, promotion
and support for smoking cessation, mass media, com-
munity interventions, surveillance, research), to be
coordinated by a central organizing body. Because of
the politically sensitive nature of the structure of the
central organizing body, we did not include a recom-
mendation for the structure of that body.
4 - Refinement of the plan by comparing it to existing
comprehensive plans
We added a category for monitoring which included
monitoring of tobacco industry activities and moni-
toring of effects of implemented interventions. Nei-
Figure 1 Framework for developing a comprehensive tobacco control program
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Table 2: Strategies and interventions recommended by the Tobacco Control 2020 Committee (Summary version)
ESTABLISHMENT OF A CENTRAL BODY A central body, with appropriate authority and budget, for coordinating and implementing 
strategies for reducing tobacco use and exposure to second hand smoke (SHS) including the 
recommendations of the Healthy Israel 2020 subcommittee, and fulfilling FCTC obligations.
TAXATION OF TOBACCO PRODUCTS AND USE OF REGULATORY MECHANISMS Increase in taxation on all tobacco products, imports and local.
Preventing exposure to SHS Absolute ban on smoking in public places including workplaces; 
Ban on smoking in special open spaces like public swimming pools, beaches, bus stops and 
train stations; Ban on smoking inside private motor vehicles where minors are present.
Advertising prohibition/Disclosure of ingredients/Preventing conflict of interest in research
LEGISLATION Prohibition of advertising tobacco products using any form of media; Prohibition of tobacco 
industry sponsorship; prohibition of point of sale advertising, together with an obligation to 
display a color poster outlining health damages from smoking at point of sale; Packaging to 
be labelled with large graphic warnings including information on smoking cessation; 
Obligatory disclosure by tobacco companies of all ingredients, and substances released upon 
lighting tobacco products including information on toxicology of said substances; Obligatory 
testing of tobacco products by the local authorities funded by the tobacco companies as per 
FCTC recommendations; Restriction of Academic Bodies from receiving sponsorship or 
research grants from tobacco companies.
Restriction on Tobacco Sales Prohibition of tobacco sales from automatic vending machines; 
Prohibition on sales of tobacco products via the internet or in shops exempted from full 
taxation (duty free) and in any other way without full taxation.
ENFORCEMENT Effective enforcement of all tobacco related legislation including limitation of SHS exposure 
prohibition of sales to minors, advertising, warning labels, illegal trade.
PROMOTION AND SUPPORT FOR SMOKING CESSATION Telephone hotline for smoking cessation counselling and support; Smoking cessation 
workshops; Individual smoking cessation counselling; Screening of smoking status of all 
patients by physician or other medical staff and recording in the patient's file; Brief 
counselling by physician, nurse or medical team members, use of ABC counselling method; 
Use of over-the-counter (OTC) Nicotine Replacement Therapy (NRT) or doctor-prescribed 
pharmacological agents for smoking cessation; Medication in addition to counselling; 
Counselling in addition to medication; Intensive (8 session) counselling in addition to 
medication; Counselling adolescents; Focusing of advice on smoking cessation on the 
pregnant population; Training of health care teams about smoking cessation counselling 
therapy; Subsidizing ("basket of health services") proven pharmacological and non-
pharmacological treatments for smoking cessation; Development and distribution of 
materials for "self help" smoking cessation; School based smoking cessation programs
MASS MEDIA Combination of mass media campaigns with other tobacco control efforts (legislation, 
community programs, schools etc); Improving the public's knowledge of how mass media 
influence attitudes to smoking; Prohibition of advertising or sponsorship by tobacco 
companies, including point of sale advertising; Establishment of an internet based support 
service; Changing the media's depiction of a "smoking world" by minimizing images of 
smoking celebrities, etc; Decreasing the presentation of smokers (especially of cigarettes) in 
movies, television, and the theatre;R
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COMMUNITY INTERVENTIONS Smoking cessation interventions in the workplace; Implementation of "Smoke Free Schools" 
policy; School based programs for smoking prevention; Implementation of "Smoke free Israel 
Defense Forces (IDF)" policy; Program for parents and teachers to prevent children's exposure 
to SHS.
SURVEILLANCE Development of national surveillance systems, including Surveillance of population smoking 
behaviour; Participation in the "Global Youth Surveillance System" or another similar system 
advocated by the WHO, which includes surveys of students, teachers and schools regarding 
smoking and related activities; Surveillance of exposure to secondhand smoke, knowledge 
and attitudes towards smoking according to WHO guidelines; Monitoring of governmental 
actions on tobacco control policy (including Knesset and other activities); Monitoring and 
reporting of monies received by the government from tobacco sales or other activities; 
Monitoring of governmental and HMO expenditures due to tobacco use; Monitoring of 
tobacco industry activities to promote tobacco use; Monitoring tobacco product content 
(nicotine and other substances)
RESEARCH Identification or development of successful interventions for prevention of use of tobacco 
products (especially among youth), cessation for smokers (including adolescent smokers), 
and prevention of exposure to secondhand smoke (especially among pregnant women, 
infants, and children). Particular emphasis on the use of social marketing techniques and 
workplace interventions; Research on the economic and health costs of tobacco in Israel; 
Research on the health damages caused by smoking; Research into the economic 
determinants of tobacco use.
Table 2: Strategies and interventions recommended by the Tobacco Control 2020 Committee (Summary version) (Continued)Rosen et al. Health Research Policy and Systems 2010, 8:17
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ther of those elements had previously been included
in the plan.
The comprehensive national tobacco control plan
The final set of strategies and interventions, representing
a comprehensive plan for national tobacco control, is pre-
sented in Table 2, with supporting evidence of effective-
ness in Additional File 2, Table S2.
A summary of the Healthy Israel 2020 Committee's
report was presented to the Knesset (Israeli Parliament)
as part of the Health Minister's 2008 report on smoking.
The plan has an impact on tobacco control activities of
the Ministries of Health and Education. It is expected to
gain cachet when the full Healthy Israel 2020 Initiative
report is published later this year.
Conclusions
Development of a comprehensive tobacco control plan is
a complex endeavour, involving crucial decisions regard-
ing intervention components. "Off the shelf" plans, which
need to be adapted to local settings, are available from a
variety of sources, and a multitude of individual recom-
mendations are available. The proposed framework is
based on the following steps: 1: compilation of a list of
potential interventions based on current evidence, aug-
mented with innovative suggestions; 2: modification of
that list based on local needs, philosophical principles,
and the prevailing political climate; 3: streamlining the
list by categorizing interventions into broad groupings of
related interventions; together these groupings form the
basis of a comprehensive plan, and 4: refinement of the
plan by comparing it to existing comprehensive plans.
This framework may assist others planning for smoke-
free societies. Additionally, this experience has implica-
tions for development of evidence-based health plans
addressing other risk factors.
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